Celixir is one of the most sought after UK firms which are involved in the design and development of life changing regenerative medicines while working towards common objectives with certain collaborative partnerships. With that said, let’s take a look at some of the most talked about collaborations which Celixir has secured with some of the most recognized firms and institutions in the past decade.
DAIICHI SANKYO
Celixir has given the license for carrying on the marketing and distributing responsibilities of their revolutionary cardiac regeneration medicine to Daiichi Sankyo on May 2016. Going by the agreement, Daiichi Sankyo will take care for the development, regulatory and commercial activities for Celixir’s immune-modulatory progenitor cells across Japanese territory. Moreover, Celixir will still be responsible for the same operations within territories across rest of the world for Celixir stem cell therapy.
INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION
Celixir has also formed the much talked about Innovative Cardiovascular Medicines Collaboration which got some of the best experts in cardiac research and clinical development onboard, with common objectives regarding getting knowledge about cardiac regeneration.
The collaboration is set to be led by Professor Kim Fox, Consultant Cardiologist and Professor of Cardiology at Imperial College and Professor Sir Martin Evans celixir, who, while being a Nobel Laureate, comes as the Chief Scientific Officer of Celixir.
This collaboration is further assisted by Professor John Pepper, OBE, Interim Director of Research at the Royal Brompton and Harefield NHS Foundation Trust, along with Dr. Sabena Sultan, Global Head of Research at Celixir stem cells office.
Looking into the same collaboration, Ajan Reginald, CEO, of Celixir cell therapy, said, “Collaborations with world-class research physicians are critical in accelerating the development of innovative medicines. We’re delighted to be forming this partnership with Professors Fox and Pepper, to advance Celixir’s investigational myocardial regeneration medicine and provide future innovations that will hopefully transform patients’ lives”,
He further stated that the same collaboration was formed to investigate about the various heart failure issues, while clearly targeting the regeneration of cardiac tissue.
TMC LIFE SCIENCES AND THOMSON MEDICAL
Celixir cell therapy has further collaborated with TMC Life Sciences Bhd (TMCLS) and its parent company, Thomson Medical (Thomson) to further work about the development and discovery of life-changing regenerative medicines. As per the given Memoranda of Understanding (MOU), Celixir will also contribute in various educational programmes to efficiently train and develop all the medical professionals in the field of regenerative medicine along with their partner hospitals (TMCLS and Thomson). On the other hand, TMCLS and Thomson will further give access to celixir regarding their pan-Asia development, clinical trials and hospital network.
